SecBot SecBot
SECBOTREPLAY Home › Report › ABBV

ABBV · AbbVie disclosed that Class II director Jennifer L

AbbVie Inc. · 8-K filed Nov 2, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Nov 2, 2026 at 16:05 ET

AbbVie disclosed that Class II director Jennifer L. Davis resigned from the board effective November 2, 2026, following her appointment as CEO of Align Technology. The resignation is not due to any dispute with AbbVie. This is a routine board departure with no material financial impact.

  • Jennifer L. Davis, a Class II director, resigned from AbbVie's board effective November 2, 2026.
  • Resignation was due to her recent appointment as CEO of Align Technology, Inc.
  • The filing states the resignation is not the result of any dispute or disagreement with AbbVie.
  • No replacement was named in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access